Deborah Hamby, M.D.
NPI 1972503183 · Specialist · Roseville, MI
Enrolled with Medicare as Practitioner - Obstetrics/Gynecology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1972503183
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- No
- License
- 061399 (MI)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
955 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 166 | $135 |
| Urinalysis, Manual Test81002 | 152 | $3 |
| Colorectal Cancer Screening; Fecal Occult Blood Test, Immunoassay, 1-3 SimultaneousG0328 | 141 | $18 |
| Annual Depression Screening, 5 to 15 MinutesG0444 | 106 | $20 |
| Pelvic Exam99459 | 87 | $23 |
| Screening 3d Breast Mammography77063 | 86 | $55 |
| Screening Mammography |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 14 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Estradiol | 102 | 41 |
| Alendronate Sodium | 37 | — |
| Raloxifene Hcl | 34 | — |
| Clotrimazole/Betamethasone Dipbrand: Clotrimazole-Betamethasone | 31 | 17 |
| Clobetasol Propionate | 22 | 13 |
| Estradiol/Norethindrone Acetbrand: Estradiol-Norethindrone Acetat | 18 | — |
| Valacyclovir Hclbrand: Valacyclovir | 17 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$268 across 14 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-07-29
- Last updated
- 2014-03-11
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.